Publications

Thanawastien A*, Joyce KE*, Cartee RT, Haines, LA, Pelton SI, Tweten RK, Killeen KP. Preclinical in vitro and in vivo profile of a highly-attenuated, broadly efficacious pneumolysin genetic toxoid. Vaccine. 2020 Jun 9; S0264-410X(20)30581-8. doi: 10.1016/j.vaccine.2020.04.064. (*equally contributing authors).

 

Cartee RT, Thanawastien A, Griffin IV TJ, Mekalanos JJ, Bart S, Killeen KP. A phase 1 randomized safety, reactogenicity, and immunogenicity study of Typhax: A novel protein capsular matrix vaccine candidate for the prevention of typhoid fever. PLoS Negl Trop Dis. 2020 Jan 6;14(1):e0007912. doi: 0.1371/journal.pntd.0007912. eCollection 2020 Jan.

 

Griffin TJ 4th, Thanawastien A, Cartee RT, Mekalanos JJ, Killeen KP. In vitro characterization and preclinical immunogenicity of Typhax, a typhoid fever protein capsular matrix vaccine candidate. Hum Vaccine Immunother. 2019;15(6):1310-1316. doi: 10.1080/21645515.2019.1599674. Epub 2019 May 28.

 

Thanawastien A, Cartee RT, Griffin TJ 4th, Killeen KP, Mekalanos JJ. Conjugate-like immunogens produced as protein capsular matrix vaccines. Proc Natl Acad Sci U S A. 2015 Mar 10;112(10):E1143-51. doi:10.1073/pnas.1425005112. Epub 2015 Feb 19.

© 2020 Matrivax Research and Development Corporation

650 Albany Street, Suite 117, Boston, MA 02118

LI-In-Bug.png